Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Gynecol Oncol. 2017 Sep 28;147(3):503–508. doi: 10.1016/j.ygyno.2017.09.021

Figure 2.

Figure 2

Residual disease status by intraperitoneal disease dissemination patterns, among 741 patients with high-grade serous ovarian cancer. Percentages based on the number of patients in each pattern group with information on residual disease (pelvic, N=67; lower abdominal, N=110 of 111; upper abdominal, N=440 of 445, miliary, N=113 of 118).